CLOZAPINE Response in Biotype-1

PHASE4RecruitingINTERVENTIONAL
Enrollment

524

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
SchizophreniaSchizoaffective DisorderBipolar 1 Disorder
Interventions
DRUG

clozapine

Biotype 1 and Biotype 2

DRUG

risperidone

Biotype 1 and Biotype 2

Trial Locations (5)

30602

RECRUITING

University of Georgia, Athens

60615

RECRUITING

University of Chicago, Chicago

75235

RECRUITING

UT Southwestern Medical Center, Dallas

06106

RECRUITING

Hartford Healthcare, Hartford

02115

RECRUITING

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Hartford Hospital

OTHER

collaborator

University of Georgia

OTHER

collaborator

University of Chicago

OTHER

lead

University of Texas Southwestern Medical Center

OTHER

NCT04580134 - CLOZAPINE Response in Biotype-1 | Biotech Hunter | Biotech Hunter